• 01/19/2026, Sophia Antipolis, France

    Median Technologies reports landmark 2025 performance with major regulatory and commercial milestones ahead in 2026

    Median made outstanding progress in 2025 which provides the foundations to deliver significant achievements in the coming years.  Median has achieved key regulatory, commercial, and operational milestones, providing significant momentum for further accelerating its growth trajectory to create long term value for shareholders and clients
    Read more Download 20250119_PR_FY2025keybusinessresults_EN_Final-1.pdf
  • 01/14/2026, Sophia Antipolis, France

    H1 2026 Financial Communication Calendar

    Press release – For immediate release – 5:45 pm CET H1 2026 Financial Communication Calendar Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and […]
    Read more Download 20260114_PR_H120226fincom_Final.pdf
  • 01/07/2026, Sophia Antipolis, France

    Half year Median Technologies liquidity contract statement

    Half year liquidity contract for the seconf half of 2025
    Read more Download 20260107_PR_LiquiditycontractS22025_EN.pdf
  • 01/05/2026, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of December 31, 2025

    Disclosure of total number of voting rights and number of shares in the capital as of December 31, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20260105_PR_shares_votingrights_Dec2025.pdf
  • 12/08/2025, Sophia Antipolis, France

    Median Technologies partners with leading U.S. healthcare company to bring eyonis® LCS to patients across the U.S. and Europe

    The collaboration will leverage the commercial partner’s robust infrastructure and broad market reach in both the U.S. and Europe to ensure efficient distribution of eyonis® LCS, once regulatory clearances are granted in the U.S., then in Europe. Both companies will collaborate closely in a structured and coordinated manner to ensure a strong impact following 510(k) clearance. The commercial phase of this collaboration is expected to begin once Median Technologies will have obtained 510(k) clearance for eyonis® LCS from the US FDA, which is anticipated in early Q1 2026.
    Read more Download 20251208_PR_Partnership_EN_Final.pdf
  • 12/03/2025, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of November 30, 2025

    Disclosure of total number of voting rights and number of shares in the capital as of November 30, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20251203_PR_shares_votingrights_Nov2025.pdf
  • 11/25/2025, Sophia Antipolis, France

    Median Technologies to showcase AI-powered Software as a Medical Device eyonis® LCS for lung cancer screening at the RSNA 2025 Annual Meeting

    Median Technologies will attend the Radiological Society of North America (RSNA) 2025 Annual Meeting in Chicago, Il, USA, from Nov 30-Dec. 4, 2025. Median iCRO and eyonis® teams will welcome interested parties at Booth #5438, AI Showcase, South Hall, Level 3, McCormick Place, from Nov 30 – Dec 3 (technical exhibits dates).
    Read more Download 20251125_PR_RSNA2025_EN.pdf
  • 11/13/2025, Sophia-Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of October 31, 2025

    Disclosure of total number of voting rights and number of shares in the capital as of October 31, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20251113_PR_shares_votingrights_oct2025.pdf
  • 11/03/2025, Sophia Antipolis, France

    Median Technologies appoints Didric Cederholm to its Board of Directors

    Didric Cederholm is a Founding Partner and the Chief Investment Officer of Lion Point Capital, a global special situations investment fund. Prior to founding Lion Point Capital, Didric spent nearly eight years at Elliott Management and was previously a Principal at Eos Partners.
    Read more Download 20251103_PR_BoardAppointment_EN_final.pdf
  • 10/23/2025, Sophia Antipolis, France

    Median Technologies reports first-half 2025 financial results and provides key Q3 2025 business results

    Median Technologies today reported its consolidated financial results for the six month period ending June 30, 2025 and provided key business results (unaudited) for the third quarter of 2025.
    Read more Download 20251023_HY2025andQ3_EN_final.pdf
    • 1 … 44